Live Breaking News & Updates on Tiagor Matos

Stay updated with breaking news from Tiagor matos. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Novel Subcutaneous Biologics Show Promise in AD

Patients with moderate to severe atopic dermatitis could soon have more therapeutic options, with monoclonal antibodies targeting novel immune pathways that reduce disease severity, suggest two trials. ....

United States , Noord Holland , Eric Simpson , Stephan Weidinger , Tiagor Matos , Department Of Dermatology , European Academy Of Dermatology , Kymab Ltd , University Hospital Schleswig Holstein , Amsterdam University Medical Centers , Oregon Health Science University , European Academy , Eczema Area , Severity Index , Oregon Health , Science University , Medscape Medical News , Validated Investigator Global Assessment , Atopic Dermatitis , Body Surface Area , Peak Pruritus Numerical Rating Scale , Biologic Therapy , Monoclonal Antibody , Corneal Disease , Preventive Screening , Severity Indices ,

Nemolizumab Promise for Prurigo Nodularis Continues

Results from OLYMPIA 1 provide further support for nemolizumab as a potential first-in-class prurigo nodularis treatment; in another study, a JAK inhibitor was beneficial in patients with PN. ....

Noord Holland , United States , Tiagor Matos , Shawn Kwatra , Galderma Incyte , Nemolizumab Mitchga , University Hospital , Johns Hopkins University , Amsterdam University Medical Centers , European Academy Of Dermatology , Monasterium Laboratory Skin Hair Research Solutions Gmb , Johns Hopkins Itch Center , European Academy , Chronic Pruritus , Medscape Medical News , Hopkins University , Monasterium Laboratory Skin , Hair Research Solutions , Presented October , Biologic Therapy , Prurigo Nodularis , Skin Lesion , Atopic Dermatitis , Sleep Disorder , Patient Safety , Quality Of Life ,